sRAGE Biomarker for BAV Disease Diagnosis and Aortopathy Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Bicuspid Aortic Valve (BAV) disease and aortopathies are inadequate, as they fail to accurately predict the risk of aortic dissection and rupture, particularly in BAV patients, and lack a reliable assessment for subsequent aortopathy development.
Innovation Solution
Determining the level of soluble Receptor for Advanced Glycation Endproducts (sRAGE) in biological samples and comparing it to control levels to identify and treat BAV disease and aortopathies, with increased sRAGE levels indicating the presence of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If echocardiography is used for diagnosing BAV, then diagnostic accuracy is improved in mild cases, but sensitivity and specificity drop to 67% and 69% in severe stenosis with calcification
Solution Approach 1:
The patent introduces sRAGE (soluble Receptor for Advanced Glycation Endproducts) as an intermediary biomarker that mediates the diagnostic challenge. Instead of relying solely on direct imaging of the calcified valve, sRAGE levels in blood serve as a proxy indicator that correlates with BAV presence and aortopathy risk, thereby maintaining diagnostic accuracy in severe cases where echocardiography fails.
Solution Approach 2:
The patent replaces the mechanical imaging system (echocardiography) with a biochemical detection system (sRAGE blood test). This substitution allows diagnosis to continue functioning in severe stenosis cases where the mechanical imaging approach fails due to calcification, achieving the goal of maintaining diagnostic reliability across all severity levels.
2Measurement precision
If CT scan is used for measuring aortic diameter, then measurement sensitivity is improved, but the ability to assess risk for subsequent aortopathy development remains unavailable
Solution Approach 1:
The patent makes the sRAGE test universal by enabling it to serve multiple functions: (1) diagnosing BAV presence, (2) assessing aortopathy risk, and (3) predicting adverse events. This multi-functionality resolves the contradiction by providing both measurement precision and risk assessment information through a single biomarker-based approach, whereas CT scans can only provide anatomical measurements without risk prediction capability.
Solution Approach 2:
sRAGE acts as an intermediary that bridges the gap between anatomical measurement (aortic diameter) and functional risk assessment. By correlating sRAGE levels with both valve morphology and aortic disease progression, the test provides risk information that CT scans cannot obtain, thereby resolving the information loss problem.
3Ease of manufacture
If aortic diameter threshold of 5.5 cm is used for surgery recommendation, then surgical intervention is standardized, but more than 60% of patients with acute aortic dissection would fail to prevent the majority of acute aortic dissections
Solution Approach 1:
The patent enables preliminary identification of high-risk patients through sRAGE testing before acute dissection occurs. By detecting elevated sRAGE levels that predict aortopathy development, clinicians can initiate preventive measures earlier in the disease course, thereby preventing the majority of acute aortic dissections that would otherwise occur in patients meeting the 5.5 cm diameter criterion.
Solution Approach 2:
The sRAGE test provides feedback about individual aortopathy risk that goes beyond the fixed diameter threshold. This feedback mechanism allows dynamic adjustment of surgical timing and intensity based on actual risk stratification, improving dissection prevention effectiveness while maintaining guideline standardization through objective biomarker measurement.
4Reliability
If aggressive surgical guidelines are adopted for BAV patients, then aortic replacement is recommended more frequently, but over 20% of patients would not have qualified for preventive aortic replacement
Solution Approach 1:
The patent introduces dynamic risk stratification through sRAGE levels, allowing the surgical threshold to be flexible rather than fixed. Patients with elevated sRAGE levels can be identified as high-risk regardless of their aortic diameter, enabling preventive surgery in cases where traditional diameter-based guidelines would exclude them, thereby improving management effectiveness while maintaining adaptability to individual patient needs.
Data Source
AI summary
Provided herein are methods for identifying and treating BAV disease and/or aortopathy in a subject, and methods of improving outcome in a subject. The subject may be asymptomatic of BAV disease and/or aortopathy, experiencing symptoms of BAV disease and/or aortopathy, have BAV disease and/or aortopathy, or be a blood relative of an individual having BAV disease and/or aortopathy. Levels of sRAGE in the subject's biological sample are determined, compared to a control biological sample, and used as an indicator for the presence and severity of BAV disease and/or aortopathies, a tool to screen family members, and an indicator of the proper surgical or treatment regimens.